R&D News | pharmaphorum

News

AstraZeneca links with Absci on AI for biologics discovery

AstraZeneca has agreed a deal worth up to $247 million with US generative artificial intelligence (GenAI) company Absci that will focus on the discovery of a new antibody-

News

MSD, Amgen back patient data specialist Culmination Bio

The venture capital arms of MSD and Amgen have provided $10 million in funding to Culmination Bio, a Utah start-up that aims to build the largest disease-agnostic patient

News

AZ drops two trials aimed at expanding Lokelma’s label

AstraZeneca has decided to abandon two phase 3 trials of its drug to reduce high levels of potassium in the blood (hyperkalaemia) – Lokelma – in patients with kidney disea

News

Cybin preps for ph3 as psychedelic clears depression trial

Cybin has unveiled phase 2 results with its psychedelic medicine for major depressive disorder, which it says support moving the drug into a phase 3 programme.

News

AbbVie agrees $10.1bn deal to buy ImmunoGen

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovar

News

Could high HDL-cholesterol raise dementia risk?

A new study has added to data suggesting that HDL cholesterol (HDL-c) – sometimes called ‘good’ cholesterol, as it can help protect against heart disease – may be a risk f

AstraZeneca links with Absci on AI for biologics discovery

MSD, Amgen back patient data specialist Culmination Bio

AZ drops two trials aimed at expanding Lokelma’s label

Cybin preps for ph3 as psychedelic clears depression trial

AbbVie agrees $10.1bn deal to buy ImmunoGen

Could high HDL-cholesterol raise dementia risk?

UK backs start-up Potential Sciences' AI-powered drug hunt

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks